155 related articles for article (PubMed ID: 22616103)
1. Skies darken over drug companies.
Holmes D
Lancet; 2012 May; 379(9829):1863-4. PubMed ID: 22616103
[No Abstract] [Full Text] [Related]
2. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
Garrigues A
J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
[No Abstract] [Full Text] [Related]
3. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
4. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
Ablavsky G; Larrimore Ouellette L
JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
[No Abstract] [Full Text] [Related]
5. Going over the patent cliff.
Schommer JC
Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
[No Abstract] [Full Text] [Related]
6. Pharmaceutical R&D: an age of change?
Baldwin JJ
Future Med Chem; 2014 Jun; 6(10):1109-12. PubMed ID: 25078132
[No Abstract] [Full Text] [Related]
7. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
Tu SS; Sarpatwari A
N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
[No Abstract] [Full Text] [Related]
8. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
Huskamp HA
Health Aff (Millwood); 2006; 25(3):635-46. PubMed ID: 16684726
[TBL] [Abstract][Full Text] [Related]
9. The importance of being first: evidence from Canadian generic pharmaceuticals.
Hollis A
Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
[TBL] [Abstract][Full Text] [Related]
10. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
11. Drug Regulation and Pricing--Can Regulators Influence Affordability?
Eichler HG; Hurts H; Broich K; Rasi G
N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
[No Abstract] [Full Text] [Related]
12. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
13. Patent cliff mitigation strategies: giving new life to blockbusters.
Kakkar AK
Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
[TBL] [Abstract][Full Text] [Related]
14. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
15. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
16. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
Brockmeier MS
Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
[No Abstract] [Full Text] [Related]
17. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.
Feldman R; Lobo F
Eur J Health Econ; 2013 Aug; 14(4):667-75. PubMed ID: 22815099
[TBL] [Abstract][Full Text] [Related]
18. Competition body rules that drug companies "abused" their position.
Sidley P
BMJ; 2003 Oct; 327(7421):946. PubMed ID: 14576226
[No Abstract] [Full Text] [Related]
19. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
20. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
Micklus A; Muntner S
Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
[No Abstract] [Full Text] [Related]
[Next] [New Search]